reinthas



William Slattery, CFA Vice President Listing Qualifications

By Electronic Mail

September 24, 2013

Mr. Jeffrey Thomas Chief, IT Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Received SEC

1-36075

NASDAQ

THE NASDAQ OMX GROUP

SEP 2 4 2013

Washington, DC 20549

Dear Mr. Thomas:

This is to certify that on September 17, 2013 The Nasdaq Stock Market (the "Exchange") received from Evoke Pharma, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, par value \$0.0001 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery